Prevention & lipidsDiagnostic or prognostic study
Multinational validation of the PREVENT and SCORE2 cardiovascular risk equations across 6.4 million individuals
- Multinational external validation study of risk prediction equations
- 44 observational cohorts
- 18 randomized trials
- multiregional
Scaling factors created for PREVENT risk prediction over 1-9 years
Authors' conclusion
Despite differences in CVD outcome definitions, target populations and predictor variables, overall discrimination and calibration were similar for both equations, with generally good performance across regions, including in multiregional randomized trials.
Study context
- Population
- Individuals in observational cohorts and randomized trials across North America, Europe and Asia/Other or multiregional trials44 cohorts · 18 trials
- Participants
- 6,422,714 vs 5,437,384
- Comparison
- PREVENT vs SCORE2 cardiovascular disease (CVD) risk equations
- PREVENTn = 6,422,714
- SCORE2n = 5,437,384
- Outcome
- Discrimination and calibration of the two risk algorithms across geographical regions
Performance
As reported in the abstract
Discrimination and calibration · 5.1 years mean follow-up
| Test or model | Total CVD events (fatal and non-fatal atherosclerotic cardiovascular disease (ASCVD) or heart failure (HF)) | CVD events (MI, stroke or CV death) |
|---|---|---|
| PREVENT | 293,737 | |
| SCORE2 | 258,086 |
Original publication
Multinational validation of the PREVENT and SCORE2 cardiovascular risk equations across 6.4 million individuals. Nat Med. Published 5 May 2026. doi:10.1038/s41591-026-04437-z
Summarised from the published abstract; every number is checked against it